PF-07265807

N/A

Report date: 2025/06/10 17:55:10
NME

Base Information

Drug NamePF-07265807
Drug Alias NamePF-07265807ARRY-067PF-5807
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsHepatocyte growth factor receptor inhibitorsTyrosine-protein kinase Mer inhibitors +[4] 
TargetsAXL receptor tyrosine kinaseHepatocyte growth factor receptorTyrosine-protein kinase Mer +[4] 
Therapy Area/IndicationsSolid tumoursNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncPfizer Investment Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A